Form 4: Arcutis CFO Sells Shares for Tax Obligations

Arcutis Biotherapeutics' SVP Chief Financial Officer, Latha Vairavan, sold 1,320 shares of common stock on February 2, 2026, to cover tax withholding obligations related to RSU vesting.

Summary

• Latha Vairavan, SVP Chief Financial Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• The transaction involved the disposition of 1,320 shares of common stock on February 2, 2026.
• The shares were sold at a weighted average price of $25.4984 per share, with individual sales ranging from $24.745 to $25.68.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted on January 12, 2024, with 25% vesting annually on February 1st of each year, commencing February 1, 2025, contingent on continued service.
• Following this transaction, Latha Vairavan directly beneficially owns 63,607 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which is a common occurrence for executives receiving equity compensation.

Positives

• The underlying grant of Restricted Stock Units (RSUs) to the SVP Chief Financial Officer indicates ongoing executive compensation and alignment with shareholder interests.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned and non-discretionary sale.

Negatives

• The sale of 1,320 shares by a senior executive, even for tax purposes, results in a minor reduction in direct insider ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on a past insider transaction.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ('RSUs').
• The RSUs were granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of equity awards, such as RSUs, are a routine and common practice across all industries, particularly in the biotechnology sector where equity compensation is prevalent. Such transactions are typically non-discretionary and do not usually signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the transaction is for tax purposes and not indicative of a change in management's confidence.
• Employees: No direct impact, but the RSU vesting demonstrates the company's executive compensation structure.

Next Steps

• Future annual vesting of the remaining Restricted Stock Units on February 1st of subsequent years, subject to Latha Vairavan's continued service to Arcutis Biotherapeutics.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by a senior executive to cover tax obligations related to RSU vesting. This type of transaction is common and does not provide new material information that would significantly alter the investment thesis for Arcutis Biotherapeutics. Therefore, a 'hold' recommendation is appropriate, as the event itself does not warrant a change in investment strategy.

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Executive Compensation, Latha Vairavan, Tax Withholding